BioCentury
ARTICLE | Clinical News

Tyme reports Phase I data of SM-88 in metastatic cancer

September 29, 2017 9:25 PM UTC

Tyme Technologies Inc. (NASDAQ:TYME) reported data from an open-label Phase I trial in 30 patients with progressive metastatic cancer showing that SM-88 (TYME-88, SM88) led to 8 complete or partial tumor responses according to RECIST 1.1 criteria, plus 19 cases of stable disease. In patients achieving stable disease, SM-88 led to a median overall survival (OS) of 29 months...

BCIQ Company Profiles

Tyme Technologies Inc.